



Athena receives 1st approval for SR formulation of Metformin in UK

April 2017 :

Athena DDS, a technology driven company specialized in Oral Solid Dosage forms, deepens its roots in UK market with Metformin 750 mg SR Tablet registration.

'We are proud to announce our successful registration of Metformin 750 mg SR Tablet following submission in June 2015. With this Athena is gaining penetration in EU markets' declares Alexandre Williams, Managing director of Athena DDS.

Metformin is a type 2 diabetic drug which helps diabetics to respond normally to insulin. Like most diabetic drugs, the ultimate goal of Metformin is to lower blood sugar to a normal level and maintain this level with our SR Tablet.

For more information, please contact:

Mr. Alexandre Williams, MD. Email: awilliams@ddsathena.com

About Athena DDS:

Athena with its EU GMP approved facility and state of art R&D Centre is focused on the innovative and value added products in mature and emerging markets and is engaged in Licensing and Development model for Specialty Pharma, Multinationals and other established companies. Athena provides comprehensive product lifecycle management solutions for Oral Solids based on its proprietary technology platforms. Athena has already developed many innovative products CTD format viz., Domperidone ODT, Fenofibrate 160, 200 & 267 Capsule, Levocetirizine ODT, Meloxicam ODT, Metformin SR Tablets 750mg, Ondansetron ODT, Secnidazole High Dose 2 grams Sachet as one shot treatment, Racecadotril Sachets 10mg & 30mg, Tramadol Paracetamol ODT, Voglibose ODT and Zolpidem ODT & SL ODT. These products are already marketed by leading companies across geographies or are under registration.

For further information, please visit www.athenadds.com